Last Updated : October 25, 2023
Details
Generic Name:
brentuximab vedotin
Project Status:
Withdrawn
Therapeutic Area:
Hodgkin lymphoma
Manufacturer:
Seagen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0311-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of previously untreated patients with advanced stage HL, in combination with doxorubicin, vinblastine, and dacarbazine.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Adcetris (brentuximab vedotin for injection) is indicated for the treatment of previously untreated patients with advanced stage Hodgkin lymphoma (HL), in combination with doxorubicin, vinblastine, and dacarbazine.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 08-Mar-23 |
|---|---|
| Call for patient/clinician input closed | 02-May-23 |
| Clarification: - Patient input submission received from Lymphoma Canada | |
| Submission received | 12-Apr-23 |
| Submission accepted | 26-Apr-23 |
| Review initiated | 27-Apr-23 |
| Draft CADTH review report(s) provided to sponsor for comment | 19-Jul-23 |
| Deadline for sponsors comments | 28-Jul-23 |
| Clarification: - Submission was voluntarily withdrawn by sponsor on 23-Oct-23 | |
Last Updated : October 25, 2023